Perpetual Ltd Buys 121,999 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Perpetual Ltd has increased its holdings in Thermo Fisher Scientific Inc. by 43.9%, acquiring an additional 121,999 shares, bringing their total to 399,937 shares valued at $162.16 million.
• The stock's current market capitalization is $181.57 billion, with a recent PE ratio of 27.81 and a **price-to-earnings-growth ratio** of 2.52.
• Thermo Fisher Scientific recently reported quarterly earnings of $5.36 per share, exceeding analysts' expectations, and has also declared a quarterly dividend of $0.43 per share.

Perpetual Ltd increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 43.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 399,937 shares of the medical research company's stock after buying an additional 121,999 shares during the period. Thermo Fisher Scientific accounts for about 1.9% of Perpetual Ltd's investment portfolio, making the stock its 12th biggest position. Perpetual Ltd owned about 0.11% of Thermo Fisher Scientific worth $162,158,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in TMO. Mondrian Investment Partners LTD raised its position in Thermo Fisher Scientific by 146.1% during the first quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock valued at $106,738,000 after purchasing an additional 127,357 shares during the period. Foresight Group Ltd Liability Partnership raised its position in Thermo Fisher Scientific by 3,242.7% during the first quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company's stock valued at $29,113,000 after purchasing an additional 56,747 shares during the period. Advisors Capital Management LLC raised its position in Thermo Fisher Scientific by 6.7% during the first quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company's stock valued at $63,201,000 after purchasing an additional 7,967 shares during the period. Ilmarinen Mutual Pension Insurance Co raised its position in Thermo Fisher Scientific by 5.3% during the first quarter. Ilmarinen Mutual Pension Insurance Co now owns 67,300 shares of the medical research company's stock valued at $33,488,000 after purchasing an additional 3,400 shares during the period. Finally, GAMMA Investing LLC raised its position in Thermo Fisher Scientific by 22.0% during the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock valued at $2,419,000 after purchasing an additional 877 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TMO. William Blair began coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating on the stock. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. Wells Fargo & Company cut their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research note on Thursday, July 24th. Hsbc Global Res cut Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Finally, Barclays raised Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $490.00 to $550.00 in a research note on Thursday, September 11th. Sixteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $588.35.

Thermo Fisher Scientific Trading Down 0.2%

NYSE:TMO traded down $1.08 during midday trading on Friday, hitting $480.02. The stock had a trading volume of 4,241,401 shares, compared to its average volume of 1,433,914. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $623.77. The company has a market capitalization of $181.26 billion, a price-to-earnings ratio of 27.76, a PEG ratio of 2.56 and a beta of 0.75. The stock has a 50-day moving average of $472.01 and a 200 day moving average of $449.50. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter in the prior year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

Insider Buying and Selling

In other news, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock valued at $14,182,963 over the last quarter. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.